NEXTEER (01316) announced its interim results, with profit attributable to equity holders reaching $85.806 million, a year-on-year increase of 35.17%.

18:04 12/08/2026

Nexter (01316) announced its mid-term results for 2026, with a revenue of $2.329 billion, a year-on-year increase of 3.86%; the profit attributable to equity holders of the company was $85.606 million, a year-on-year increase of 35.17%; earnings per share were $0.034.

NEXTEER (01316) released its mid-term results for 2026, with revenue of $2.329 billion, an increase of 3.86% year-on-year; the profit attributable to equity holders of the company was $85.806 million, up 35.17% year-on-year; earnings per share were $0.034.

ORIENTAL EXPL (00430) issues a profit warning, expecting that integrated profit attributable to shareholders for the first half of the year will decrease to approximately HK$3 million to HK$3.2 million.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-7590 injection has obtained the Drug Clinical Trial Approval Notification.

CHINA RES LAND (01109) reported a cumulative contract sales amount of approximately 130.6 billion yuan for the first seven months, an increase of 5.7% year-on-year.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-7590 injection has obtained the Drug Clinical Trial Approval Notification.

CHINA RES LAND (01109) reported a cumulative contract sales amount of approximately 130.6 billion yuan for the first seven months, an increase of 5.7% year-on-year.